ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2019
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
Open access · bronzeAbstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2021Pooled it
- Determining the metabolic profile measured using ultra-high pressure liquid chromatography associated with Beta Amyloid burden in the brain in individuals with mild cognitive impairment.Research square · 2026Article
- Article
- Integrative Metabolomics, Pharmacoinformatics and Experimental Studies Reveal the Neuroprotective Potential ofMarine drugs · 2025Article
- Insulin resistance and cognitive decline: the metabolic mechanisms linking type 2 diabetes to Alzheimer's disease.Diabetology international · 2025Review
- An interpretable generative multimodal neuroimaging-genomics framework for decoding Alzheimer's disease.Journal of neural engineering · 2025Article
- Gut microbiota and blood metabolites: unveiling their roles in hippocampal volume changes through Mendelian randomization and mediation analysis.Metabolic brain disease · 2025Article
- Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.Journal of extracellular vesicles · 2025Article
- Risk of Alzheimer's disease and genetically predicted levels of 1400 plasma metabolites: a Mendelian randomization study.Scientific reports · 2024Article
- Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification.Molecules (Basel, Switzerland) · 2024Review
- Metabolic phenotyping reveals an emerging role of ammonia abnormality in Alzheimer's disease.Nature communications · 2024Article
- Human Cerebrospinal Fluid Sample Preparation and Annotation for Integrated Lipidomics and Metabolomics Profiling Studies.Molecular neurobiology · 2024Article
- Serum Bile Acids Improve Prediction of Alzheimer's Progression in a Sex-Dependent Manner.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The Incidence, Risk Factors, and Predictive Model of Obstructive Disease in Post-Tuberculosis Patients.International journal of chronic obstructive pulmonary disease · 2024Article
- Investigating the Underlying Mechanisms ofMolecules (Basel, Switzerland) · 2023Article
- The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury.Alzheimer's research & therapy · 2023Article
- Seasonal Monitoring of Volatiles and Antioxidant Activity of Brown AlgaMarine drugs · 2023Article
- Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis.International journal of molecular sciences · 2022Article
- Associations among drinking water quality, dyslipidemia, and cognitive function for older adults in China: evidence from CHARLS.BMC geriatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 20 institutions in 11 countries.
Min KimInstitute of Pharmaceutical Science, King's College London, London, UK; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
Stuart SnowdenInstitute of Pharmaceutical Science, King's College London, London, UK; Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Biochemistry, University of Cambridge, Cambridge, UK.
Tommi SuvitaivalSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Ashfaq AliSteno Diabetes Center Copenhagen, Gentofte, Denmark.
David J MerklerDepartment of Chemistry, University of South Florida, Tampa, FL, USA.
Tahmina AhmadInstitute of Pharmaceutical Science, King's College London, London, UK.
Sarah WestwoodDepartment of Psychiatry, University of Oxford, Oxford, UK.
Alison BairdDepartment of Psychiatry, University of Oxford, Oxford, UK.
Petroula ProitsiInstitute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Alejo Nevado-HolgadoDepartment of Psychiatry, University of Oxford, Oxford, UK.
Abdul HyeSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Isabelle BosAlzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Stephanie VosAlzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Rik VandenbergheUniversity Hospital Leuven, Leuven, Belgium.
Charlotte TeunissenNeurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Mara Ten KateNeurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Philip ScheltensDepartment of Neurology, Alzheimer Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Silvy GabelUniversity Hospital Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Karen MeersmansUniversity Hospital Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Olivier BlinService de Pharmacologie Clinique et Pharmacovigilance, Institut de Neurosciences des Systèmes, Aix Marseille University, APHM, INSERM, Marseille, France.
Jill RichardsonNeurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK.
Ellen De RoeckInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Kristel SleegersInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium; Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Flanders, Belgium.
Régis BordetUniversity of Lille, INSERM, CHU, Degenerative and Vascular Cognitive Disorders, Lille, Lille, France.
Lorena RamiAlzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic-IDIBAPS, Barcelona, Spain.
Petronella KettunenInstitute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Memory Clinic at Department of Neuropsychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden; Nuffield Department of Clinical Neurosciences, University of Oxford, West Wing, John Radcliffe Hospital, Oxford, UK.
Magda TsolakiFirst Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece.
Frans VerheyAlzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Isabel SalaMemory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Alberto LléoMemory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Gwendoline PeyratoutUniversity Hospital of Lausanne, Lausanne, Switzerland.
Mikel TaintaCITA-Alzheimer Foundation, San Sebastian, Spain.
Peter JohannsenDanish Dementia Research Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Yvonne Freund-LeviDepartment of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden; Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Lutz FrölichDepartment of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.
Valerija DobricicLübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Germany.
Sebastiaan EngelborghsInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium; Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Germany; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.
Giovanni B FrisoniUniversity of Geneva, Geneva, Switzerland.
José L MolinuevoAlzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic-IDIBAPS, Barcelona, Spain; Barcelona Beta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
Anders WallinInstitute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Julius PoppUniversity Hospital of Lausanne, Lausanne, Switzerland; Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
Pablo Martinez-LageCITA-Alzheimer Foundation, San Sebastian, Spain.
Lars BertramUniversity of Lübeck, Lübeck, Germany.
Frederik BarkhofNeurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Nicholas AshtonSteno Diabetes Center Copenhagen, Gentofte, Denmark; Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowInstitute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK.
Johannes StrefferExperimental Medicine, Janssen Pharmaceutical Companies, Beerse, Belgium.
Pieter J VisserAlzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands; Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Simon LovestoneDepartment of Psychiatry, University of Oxford, Oxford, UK.
Cristina Legido-QuigleyInstitute of Pharmaceutical Science, King's College London, London, UK; Steno Diabetes Center Copenhagen, Gentofte, Denmark. Electronic address: cristina.legido.quigley@regionh.dk.
Steno Diabetes Center · DKUniversity of Oxford · GBTransnational University Limburg · NLUniversity of Gothenburg · SEUniversity of Lübeck · DEAmsterdam Neuroscience · NLAmsterdam University Medical Centers · NLFundacion CITA Alzheimer · ESHospital de Sant Pau · ESKing's College London · GBKU Leuven · BEAHEPA University Hospital · GRAix-Marseille Université · FRCentral Institute of Mental Health · DEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESGlaxoSmithKline (United Kingdom) · GBJanssen (Belgium) · BEKarolinska Institutet · SEMaastricht University · NLPasqual Maragall Foundation · ES
Funding
Subtraction LipidomicsR15GM107864 · NIGMS · UNIVERSITY OF SOUTH FLORIDA · PI MERKLER, DAVID J · 2015 to 2017
$386kMedical Research Council MC_PC_17215NIGMS NIH HHS R15 GM107864
Abstract
introductionA critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.
methodsThis study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.
resultsEight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory. DISCUSSION: PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.
Indexed as
Amyloid beta-PeptidesBiomarkersHippocampusMetabolomicsAgedAmyloidosisBrainCognitive DysfunctionCohort StudiesFemaleHumansMagnetic Resonance ImagingMaleMemoryMiddle AgedNeuropsychological TestsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer's diseaseAmyloidBiomarkersBrain volume measurementsCognitive function measurementsCSFDementiaEMIF-ADMetabolomicsTau
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.